Invesaro

Stocks Health care TECH

NASDAQ · Health care

BIO-TECHNE Corp (TECH)

BIO-TECHNE Corp reported revenue of $1.2B in fiscal 2026, down 0.4% from a year earlier. Net income was $181.8M, a net margin of 15.0%. Operating cash flow minus capital spending left $263.2M of free cash flow in fiscal 2026. At June 30, 2026 it held $264.7M in cash against $200M of debt. Its latest periodic report to the SEC is the annual report (10-K) filed on August 24, 2026.

Price
$72.61
+0.06% on the day · September 25, 2026
52-week range $43.20 to $72.69
Market cap
$11.4B
Revenue (FY2026)
$1.2B
-0.4% year on year
Net margin
15.0%
P/E
62.6
on FY2026 diluted EPS

What BIO-TECHNE Corp does

BIO-TECHNE Corp is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TECH.

Revenue and profit by year

Revenue
FY19: $714M $714M FY19FY20: $738.7M $738.7M FY20FY21: $931M $931M FY21FY22: $1.1B $1.1B FY22FY23: $1.1B $1.1B FY23FY24: $1.2B $1.2B FY24FY25: $1.2B $1.2B FY25FY26: $1.2B $1.2B FY26
Net income
FY19: $96.1M $96.1M FY19FY20: $229.3M $229.3M FY20FY21: $140.4M $140.4M FY21FY22: $272.1M $272.1M FY22FY23: $285.3M $285.3M FY23FY24: $168.1M $168.1M FY24FY25: $73.4M $73.4M FY25FY26: $181.8M $181.8M FY26

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2026$1.2B$251.9M$181.8M$1.16$263.2M
2025$1.2B$102.3M$73.4M$0.46$256.6M
2024$1.2B$206.7M$168.1M$1.05$236.1M
2023$1.1B$298.9M$285.3M$1.76$216.1M
2022$1.1B$296.6M$272.1M$1.66$280.4M
2021$931M$237.3M$140.4M$0.87$307.9M

Latest SEC filings

What BIO-TECHNE Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 23, 2026
  2. September 14, 2026
  3. September 14, 2026
  4. September 9, 2026
  5. September 2, 2026
  6. August 25, 2026
  7. August 24, 2026
    Annual report 10-K · period to June 30, 2026
  8. August 20, 2026
  9. August 12, 2026
  10. August 10, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 24, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about TECH

What does BIO-TECHNE Corp do?

BIO-TECHNE Corp is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TECH.

Is BIO-TECHNE Corp profitable?

Yes. In fiscal 2026 it reported net income of $181.8M on revenue of $1.2B, a net margin of 15.0%.

How much revenue does BIO-TECHNE Corp make?

In fiscal 2026 BIO-TECHNE Corp reported revenue of $1.2B. That is 0.4% less than a year earlier.

When did BIO-TECHNE Corp last report?

Its most recent periodic report is the annual report (10-K) filed on August 24, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 24, 2026.

Similar companies

Follow TECH

Get an email when BIO-TECHNE Corp files with the SEC: results, executive changes, material agreements and annual reports.

Follow TECH: get an email when it files

Where the numbers come from

Financial figures are the values BIO-TECHNE Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.